Company Snapshot

Investment Thesis

Bio-Techne supplies reagents, instruments, diagnostics, and biologics tools to life science researchers and clinicians. High-value proteins, spatial biology platforms, and diagnostics kits provide recurring revenue with attractive margins.

  • Reagent Portfolio: R&D Systems cytokines, antibodies, and assays power core business.
  • Spatial Biology: Lunaphore and ACD RNAscope enable high-growth oncology research.
  • Diagnostics: ExosomeDx and blood coagulation controls add clinical exposure.

Strategic Mix

Protein Sciences Reagents, antibodies, immunoassays
Diagnostics & Genomics Molecular assays, spatial biology
Exosome & Liquid Biopsy Diagnostic services
Geography Americas, EMEA, APAC

Mix aligns with Bio-Techne's Protein Sciences vs. Diagnostics & Genomics segments.

Recent Performance

MTD TBD
QTD TBD
YTD TBD
5Y TBD

Maxim is cueing up returns data for this security. Once the nightly supported.csv job runs, these metrics will auto-populate.

Strategic Insights

Biopharma Demand

Biologics development sustains reagent consumption.

Spatial Expansion

Integration of Lunaphore broadens presence in pathology labs.

M&A

Balance sheet supports bolt-ons that add novel content or platforms.

Latest Coverage

Curated headlines sourced from Maxim’s AI newsroom.

Loading latest coverage...